Table 1

Selected characteristics of patients that underwent radical hysterectomy for stage IB1 cervical carcinoma, by surgical approach, before and after inverse probability of treatment weighting

Before inverse probability weightingAfter inverse probability weighting
Baseline characteristicsOpen surgery
(n=402)
Minimally inv. surgery
(n=291)
P-valueOpen surgery
(n=402)
Minimally inv. surgery
(n=291)
P-value
 Age — yr48.50 (10.60)47.93 (11.51)0.5148.31 (10.75)48.10 (11.26)0.80
 Body-mass index — kg/m2 25.98 (4.73)25.49 (5.62)0.2725.92 (5.51)25.92 (4.81)0.48
Performance status ECOG (%)0.150.29
 PS 0351 (87.31)256 (87.97)353 (87.81)257 (88.31)
 PS141 (10.19)20 (6.87)37 (9.20)20 (6.87)
 Not reported10 (2.48)15 (5.15)12 (3.89)14 (4.81)
Preoperative clinical size (%)<0.0010.058
 Not evaluable8 (1.99)11 (3.78)8 (1.95)12 (4.12)
 ≤2 cm152 (37.81)151 (51.89)153 (38.10)150 (52.54)
 >2 cm242 (60.20)126 (43.29)241 (59.95)126 (43.29)
 Not reported3 (1.03)3 (1.03)
Radical histerectomy pathology report
 Largest diameter in path-report (mm)24.07 (10.13)22.57 (9.46)0.0523.66 (9.99)23.15 (9.60)0.501
Largest tumor diameter (%)0.2700.941
  ≤2 cm160 (39.80)128 (43.99)168 (41.63)120 (41.35)
  >2 cm242 (60.20)163 (56.01)235 (58.37)170 (58.65)
Final histological grade (%)0.2660.983
  Grade 159 (14.68)42 (14.43)59 (14.65)43 (14.71)
  Grade 2197 (49.0)130 (44.67)188 (46.66)135 (46.54)
  Grade 3115 (28.61)101 (34.71)127 (31.57)91 (31.39)
  Not reported31 (7.71)18 (6.19)29 (7.12)21 (7.36)
Lymphovascular space invasion (LVSI) (%)0.0610.990
  No LVSI187 (46.52)165 (56.70)204 (50.60)147 (50.55)
  Presence of LVSI162 (40.30)105 (36.08)156 (38.61)111 (38.39)
  Not reported53 (13.18)21 (7.22)43 (10.80)32 (11.06)
Depth of Invasion (%)0.0690.998
  Superficial <1/377 (19.15)65 (22.34)81 (20.23)59 (20.24)
  Intermediate>1/3 and <1/3135 (33.58)75 (25.77)121 (30.11)87 (29.86)
  Deep >2/3131 (32.59)68 (23.37)116 (28.77)85 (29.31)
  Not reported59 (14.68)83 (28.52)84 (20.89)59 (20.59)
Margins status (%)0.1510.954
  Negative357 (88.81)268 (92.10)364 (90.13)262 (90.13)
  Positive or close <2 mm45 (11.19)23 (7.90)39 (9.74)29 (9.87)
Lymph node status (%)0.1060.916
  Negative336 (83.58)256 (87.97)345 (85.74)248 (85.45)
  Positive66 (16.42)35 (12.03)57 (14.26)43 (14.55)
FIGO staging 2018 (%)0.0150.129
  IB1118 (29.35)116 (39.86)126 (31.18)107 (36.71)
  IB2207 (51.49)129 (44.33)210 (52.13)129 (44.28)
  II-III<4 cm77 (19.15)46 (15.81)67 (16.69)55 (19.01)
Post-adjuvant therapy (%)0.0020.776
  None166 (41.29)154 (52.92)191 (47.31)140 (48.40)
  Yes236 (58.71)137 (47.08)212 (52.69)150 (51.60)
  • Counts in the weighted cohort may not sum to expected totals owing to rounding. Percentages may not total 100 because of rounding, and disagreements between numbers and percentages in the weighted cohort are the result of rounding of noninteger number values. Distributions of categorical variables were compared using the chi-square test in the unweighted cohort and weighted logistic-regression models in the weighted cohort. Quantitative variables were compared using the student t-test in the unweighted cohort and weighted linear-regression models in the weighted cohort.